Sarcomatous Change after Sellar Irradiation in a Growth Hormone-Secreting Pituitary Adenoma

Canadian Journal of Neurological Sciences

Volumn 30, Issue 4, 2003, Pages 378-383

  Prabhu, Sujit S ^a   Aldape, Kenneth D ^a   Gagel, Robert F ^a   Benjamin, Robert S ^a   Trent, Jonathan C ^a   McCutcheon, Ian E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GROWTH HORMONE; IFOSFAMIDE; OCTREOTIDE; PEGVISOMANT;

ACROMEGALY; ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BEAM THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS DISEASE; HYPOPHYSIS SARCOMA; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SARCOMA; SELLA TURCICA TUMOR; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; TUMOR RECURRENCE;

EID: 0346730082     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100003115     Document Type: Article

References (36)

1. Ahmad K, Fayos JV. Pituitary fibrosarcoma secondary to radiation therapy. Cancer 1978; 42: 107-110.
2. Ahmed M, Kanaan I, Rifai A, Tulbah A, Ghannam N. An unusual treatment-related complication in a patient with growth hormone-secreting pituitary tumor. J Clin Endocrinol Metab 1997; 82: 2816-2820.
3. Coppeto JR, Roberts M. Fibrosarcoma after proton-beam pituitary ablation. Arch Neurol 1979; 36: 380-381.
4. Gnanalingham KK, Chakraborty A, Galloway M, Revesz T, Powell M. Osteosarcoma and fibrosarcoma caused by postoperative radiotherapy for a pituitary adenoma. Case report. J Neurosurg 2002; 96: 960-963.
5. Goldberg MB, Sheline GE, Malamud N. Malignant intracranial neoplasms following radiation therapy for acromegaly. Radiology 1962; 80: 465-470.
6. Greenhouse AH. Pituitary sarcoma. A possible consequence of radiation. J Am Med Assoc 1960; 190: 269-273.
7. Martin WH, Cail WS, Morris JL, Constable WC. Fibrosarcoma after high-energy radiation therapy for pituitary adenoma. AJR Am J Roentgenol 1980; 135: 1087-1090.
8. Nagatani M, Ikeda T, Otsuki H, et al. [Sellar fibrosarcoma following radiotherapy for prolactinoma]. No Shinkei Geka 1984; 12: 339-346.
9. Pieterse S, Dinning TA, Blumbergs PC. Postirradiation sarcomatous transformation of a pituitary adenoma: a combined pituitary tumor. Case report. J Neurosurg 1982; 56: 283-286.
10. Powell HC, Marshall LF, Ignelzi RJ. Postirradiation pituitary sarcoma. Acta Neuropathol (Berl) 1977; 39: 165-167.
11. Shi T, Farrell MA, Kaufmann JC. Fibrosarcoma complicating irradiated pituitary adenoma. Surg Neurol 1984; 22: 277-284.
12. Shin H, Namba H, Ishige N, et al. [Pituitary fibrosarcoma secondary to radiation therapy for the treatment of chromophobe adenoma]. No Shinkei Geka 1980; 8: 605-614.
13. Terry RD, Hyams VJ, Davidoff LM. Combined nonmetastasizing fibrosarcoma and chromophobe tumor of the pituitary. Cancer 1959; 12: 791-798.
14. Waltz TA, Brownell B. Sarcoma: a possible late result of effective radiation therapy for pituitary adenoma. Report of two cases. J Neurosurg 1966; 24: 901-907.
15. Wheelock MC. Eosinophilic adenoma of the pituitary with sarcomatous changes. Cancer Sem 1963; 3: 77-80.
16. Drake WM, Parkinson C, Besser GM, Trainer PJ. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol Metab 2001; 12: 408-413.
17. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342: 1171-1177.
18. Utiger RD. Treatment of acromegaly. N Engl J Med 2000; 342: 1210-1211.
19. Reichenthal E, Cohen ML, Manor CR, et al. Primary osteogenic sarcoma of the sellar region. Case report. J Neurosurg 1981; 55: 299-302.
20. Bots GT, Tijssen CC, Wijnalda D, Teepen JL. Alveolar soft part sarcoma of the pituitary gland with secondary involvement of the right cerebral ventricle. Br J Neurosurg 1988; 2: 101-107.
21. Jalalah S, Kovacs K, Horvath E, et al. Rhabdomyosarcoma in the region of the sella turcica. Acta Neurochir (Wien) 1987; 88: 142-146.
22. Allan CA, Kaltsas G, Evanson J, et al. Pituitary chondrosarcoma: an unusual cause of a sellar mass presenting as a pituitary adenoma. J Clin Endocrinol Metab 2001; 86: 386-391.
23. Lopes MB, Lanzino G, Cloft HJ, et al. Primary fibrosarcoma of the sella unrelated to previous radiation therapy. Mod Pathol 1998; 11: 579-584.
24. Tachibana E, Saito K, Wakabayashi T, et al. Sarcomatous transformation of a prolactinoma associated with development of a fatal internal carotid artery pseudoaneurysm-case report. Neurol Med Chir (Tokyo) 2000; 40: 427-431.
25. Nagasaka T, Nakashima N, Furui A, Wakayabashi T, Yoshida J. Sarcomatous transformation of pituitary adenoma after bromocriptine therapy. Hum Pathol 1998; 29: 190-193.
26. Patel SR. Radiation-induced sarcoma. Curr Treat Options Oncol 2000; 1: 258-261.
27. Thoren M, Hoybye C, Grenback E, et al. The role of gamma knife radiosurgery in the management of pituitary adenomas. J Neuro-Oncol 2001; 54: 197-203.
28. Thomsen J, Mirz F, Wetke R, et al. Intracranial sarcoma in a patient with neurofibromatosis type 2 treated with gamma knife radiosurgery for vestibular schwannoma. Am J Otol 2000; 21: 364-370.
29. Amine ARC, Sugar O. Suprasellar osteogenic sarcoma following radiation for pituitary adenoma. J Neurosurg 1976; 44: 88-90.
30. Lach M, Wallace CJ, Krcek J, Curry B. Radiation-associated gliosarcoma. Can Assoc Radiol J 1996; 47: 209-212.
31. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970; 39: 1-16.
32. Nabarro JD. Acromegaly. Clin Endocrinol 1987; 26: 481-512.
33. Barzilay J, Heatley GJ, Cushing GW. Benign and malignant tumors in patients with acromegaly. Arch Int Med 1991; 151: 1629-1632.
34. Remmelink M, Decaestecker C, Darro F, et al. The in vitro influence of eight hormones and growth factors on the proliferation of eight sarcoma cell lines. J Cancer Res Clin Oncol 1998; 124: 155-164.
35. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
36. Heron-Milhavet L, LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 2002; 277: 15600-15606.